London-based Causaly, which uses AI for biomedical research and drug discovery, raised a $60M Series B led by ICONIQ Growth, taking its total funding to $93M
Context & Ripple Effects
Causaly's $60M Series B extends a London arc that began with BenevolentAI's $115M round at a $2.1B valuation in 2018 — the first signal that AI drug discovery could attract growth-scale capital out of the UK. Since then the city has stacked up health-AI financings, including Huma Therapeutics' $80M Series D at a near-$1B valuation.
What has changed is where along the pipeline the money lands: Bioptimus is building a foundational AI model for biology in Paris, while Barcelona's Biorce just raised $52.5M to speed up clinical trials — the stage downstream of Causaly's research and discovery focus. Causaly's round, led by ICONIQ Growth rather than a life-sciences specialist, shows crossover tech investors now underwriting this vertical.
First-order effects
- Causaly gets $60M to scale its biomedical research platform, with its total funding reaching $93M — and ICONIQ Growth's lead signals that generalist growth funds, not only biotech VCs, are now competing for discovery-stage AI deals.
- The raise puts Causaly in direct fundraising competition with London peer BenevolentAI, which set the category's valuation benchmark five years earlier at $2.1B post-money.
Second-order effects
- Capital crowding into adjacent pipeline stages — Biorce in trials, Bioptimus in foundation models — pressures pharma buyers to pick platforms per stage, pushing vendors like Causaly toward partnerships or expansion beyond literature-driven discovery.
- For European biotech founders, a crossover-led Series B resets investor expectations for what a discovery-stage AI company can raise outside the US, tightening the market for later-stage rivals still on older valuations.
Third-order effects
- If the pattern holds, AI drug discovery consolidates into a layered stack — foundation biology models, discovery engines, trial-acceleration tools — with each layer raising against the others' benchmarks rather than in isolation.
- London's accumulation of these rounds alongside Huma and BenevolentAI reinforces Dealroom's finding that it has overtaken Paris as Europe's leading tech hub, with applied health AI as one of its anchor categories.
The trend: AI drug-discovery funding in Europe is maturing from one-off flagship rounds into stage-by-stage capital layers, with crossover investors and London as the gravitational center.